* eFFECTOR Therapeutics Inc EFTR.OQ reported a quarterly
adjusted loss of 24 cents per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 14 cents per share.
* Reported revenue was zero; analysts expected zero.
* eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of 24 cents.
* The mean earnings estimate of analysts had risen by
about 38.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* eFFECTOR Therapeutics Inc shares had risen by 53.1% this
quarter and gained 26.3% so far this year.
* The company reported a quarterly loss of $10 million.
* Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data May
9 at 10:22 p.m. UTC. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2023 -0.14 -0.24 Missed
Dec. 31 2022 -0.24 -0.22 Beat
Sep. 30 2022 -0.21 -0.23 Missed
Jun. 30 2022 -0.16 -0.17 Missed